Prescient Therapeutics Ltd has released a press release.
Prescient CEO to step down in early 2025
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Appendix 4E and 2024 Annual Report
- June 2024 Quarterly Update and Appendix 4C
- March 2024 Quarterly Update and Appendix 4C
- December 2023 Quarterly Update and Appendix 4C
- PTX-100 Ph1b results show excellent safety & efficacy in TCL
Later from Prescient Therapeutics
- September 2024 Quarterly Update and Appendix 4C
- Appointment of Chief Executive Officer
- US FDA allows PTX-100 Ph2 trial
- December 2024 Quarterly Update and Appendix 4C
- December 2024 Quarterly Update and Appendix 4C - amended
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics